跳转至内容
Merck

MAB348-AF555

Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor™ 555

clone 22C11, from mouse, ALEXA FLUOR™ 555

别名:

Amyloid beta A4 protein, ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II, PN-II, N-APP, Soluble APP-alpha, S-APP-alpha, Soluble APP-beta, S-APP-beta,

登录 查看公司和协议定价

选择尺寸

关于此项目

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物源

mouse

品質等級

100

共軛

ALEXA FLUOR™ 555

抗體表格

purified immunoglobulin

抗體產品種類

primary antibodies

無性繁殖

22C11, monoclonal

物種活性

canine, human, mouse, rat, porcine, monkey, fish

技術

immunocytochemistry: suitable

同型

IgG1

NCBI登錄號

NM_000484.2
NM_201413.1
NM_201414

UniProt登錄號

P05067

運輸包裝

wet ice

目標翻譯後修改

unmodified

基因資訊

human ... APP(351)

一般說明

Amyloid beta A4 protein (UniProt P05067; also known as ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID 351) in human. Amyloid precursor protein (APP) is initially produced with a signal peptide sequence (a.a. 1-17), the removal of which yields the mature protein with a large extracellular portion (a.a. 18-699), followed by a transmembrane segment (a.a. 700-723) and a cytoplasmic (a.a. 724-770) tail. APP can be further processed by the α-, β-, and γ-secretases in two alternative processing pathways. In the non-amyloidogenic pathway, APP is first cleaved by the plasma membrane-localized α-secretase to generate an N-terminal extracellular sAPPα fragment (a.a. 18-687) and a membrane-bound C-terminal fragment C83 (CTFα), which can be further cleaved by γ-secretase to produce a non-toxic small peptide p3 and a cytoplasmic APP intracellular domain (AICD). In the amyloidogenic pathway, APP undergoes β-cleavage in BACE-1 (β-site APP-cleaving enzyme)-enriched endosomes to generate an N-terminal extracellular sAPPβ fragment (a.a. 18-671) and a membrane-bound C-terminal fragment C99 (CTFβ). Subsequent cleavage of C99 by γ-secretase releases the amyloid β peptide (Aβ) and AICD. Aβ accumulation in the cortical and hippocampal regions of the brain is a major pathological feature of Alzheimer′s disease (AD).
~110/120/130 kDa observed.

免疫原

Epitope: Amino acids 66-81 of APP.
Purified recombinant Alzheimer precursor A4 (pre-A4695) fusion protein.

應用

Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor™ 555 is an antibody against APP A4 for use in Immunocytochemistry.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
The unconjugated antibody (Cat. No. MAB348) is shown to be suitable also for immunohistochemistry (for both frozen and paraffin-embedded sections), immunofluorescence, and Western blotting applications.

生化／生理作用

Clone 22C11 reacts with pre-A4. The antibody recognizes amino acids 66-81 of the N-terminus on the pre-A4 molecule (Hilbich, C., et al. (1993). J. Biol. Chem. 268(35):26571-26577). Clone 22C11 recognizes all three isoforms of APP, immature ~110kDa, sAPP ~120kDa, and mature ~130kDa (Hoffmann, J., et al. (2000). Eur. J. Cell. Biol.79(12):905-914.). The antibody is known to cross react with APLP2 (Slunt, H.H., et al. (1994). J. Biol. Chem. 269(4):2637-2644).

外觀

Protein A purified
Purified mouse monoclonal IgG1 antibody conjugate in PBS with 15 mg/mL BSA and 0.1 % sodium azide.

準備報告

Stable for 1 year at 2-8°C from date of receipt.

分析報告

Evaluated by Immunocytochemistry in SH-5YSY cells.

Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected APP A4 in SH-5YSY cells.

其他說明

Concentration: Please refer to lot specific datasheet.

法律資訊

ALEXA FLUOR is a trademark of Life Technologies

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品？  

试试我们的产品选型工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Neuroscience Solutions for productive research

Alzheimer’s Disease is a progressively deteriorating disease. It manifests itself with memory loss, confusion, problems with judgment, planning, concentration, and personality changes; and in it’s later stages, a decline in physical abilities. The disease’s causes, cures, and preventions are unknown; however, key proteins likely involved in the degenerative mechanism have been identified. Alzheimer’s Disease is characterized by neuronal loss, alterations in neurotransmitter systems, and the presence of neurofibrillary tangles composed of abnormally hyperphosphorylated tau proteins. A prominent feature of Alzheimer’s Disease is the formation of senile plaques in selected regions of the brain. The center of these plaques are composed mainly of fibrillary aggregates of a common, but not well understood, b amyloid peptides (Aβ). The Aβ peptides are generated from the larger amyloid-β precursor protein (APP) by the sequential action of β- and γ-secretase, and it is generally accepted that oligomeric forms of this Aβ are neurotoxic, resulting in disease progression.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持